Pfizer Study suggests Covid-19 Vaccine to blame for huge increase in Hepatitis among Children as UK Government launches Urgent InvestigationSat 10:09 am Europe/London, 9 Apr 2022
The UK Health Security Agency has announced that it has recently detected higher than usual rates of liver inflammation (hepatitis) among children, but have ruled out the common viruses that cause hepatitis so have therefore launched an urgent investigation.
The very first place they should be looking is at the experimental Pfizer Covid-19 injection that has outrageously and unncessarily been offered to children as young as five. Why? Because Pfizer’s own study proves that the mRNA jab accumulates in the liver causing hepatitis.
The UK Health Security Agency (UKHSA) has recently detected higher than usual rates of liver inflammation (hepatitis) in children. Similar cases are also being assessed in Scotland.
Hepatitis is a condition that affects the liver and may occur for a number of reasons, including several viral infections common in children. However, in the cases under investigation the common viruses that cause hepatitis have not been detected.
Hepatitis symptoms include:
- dark urine
- pale, grey-coloured poo
- itchy skin
- yellowing of the eyes and skin (jaundice)
- muscle and joint pain
- a high temperature
- feeling and being sick
- feeling unusually tired all the time
- loss of appetite
- tummy pain
UKHSA is allegedly working swiftly with the NHS and public health colleagues across the UK to investigate the potential cause. But it would appear they need not look any further than the experimental Pfizer Covid-19 injection they have outrageously been giving to children. Because Pfizer’s own study confirms the mRNA jab accumulates in the liver causing hepatitis.
It was assumed that the Covid-19 vaccine’s spike protein would remain at the injection site and last up to several weeks like other proteins produced in the body.
But as we all know assumptions make an ass out of u and me, and Pfizer’s own study shows this is not the case and that spike proteins circulate in the body following mRNA Covid-19 vaccination, and the highest concentration ends up in the liver.
“The greatest mean concentration outside the injection site was observed in the liver, with values of 27.916 μg equiv lipid/g (equivalent to 21.5 % dose) in males and 30.411 μg equiv lipid/g (equivalent to 18.4 % dose) in females”
The Japanese regulatory agency’s bio-distribution study of the Pfizer vaccine shows that the contents of the Covid-19 injection travels from the injection site, through the bloodstream, and ends up in various organs such as the liver, spleen, adrenal glands, and ovaries for at least 48 hours after injection.
In animals that received the BNT162b2 injection, reversible hepatic effects were observed, including enlarged liver, vacuolation, increased gamma-glutamyl transferase (γGT) levels, and increased levels of aspartate transaminase (AST) and alkaline phosphatase (ALP) [source].
According to the researchers’ transient hepatic effects induced by LNP delivery systems have been reported previously [sources 1,2,3,4]
This was the driver for Aldén, et al from the Department of Clinical Sciences, Lund University, to examine the effect of BNT162b2 on a human liver cell line in vitro and investigate if BNT162b2 can be reverse transcribed into DNA through endogenous mechanisms. They published their paper in Current Issues of Molecular Biology.
The authors of the paper found that when the mRNA Pfizer vaccine enters the human liver cells, it triggers the cell’s DNA which is inside the nucleus, to increase the production of the LINE-1 gene expression to make mRNA.
The mRNA then leaves the nucleus and enters the cell’s cytoplasm, where it translates into LINE-1 protein. A segment of the protein called the open reading frame-1, or ORF-1, then goes back into the nucleus, where it attaches to the vaccine’s mRNA and reverse transcribes into spike DNA.
Through conducting the study they also found spike proteins expressed on the surface of the liver cells that researchers say may be targeted by the immune system and possibly cause autoimmune hepatitis, as “there [have] been case reports on individuals who developed autoimmune hepatitis after BNT162b2 vaccination.”
The authors were referring to the first reported case of a healthy 35-year-old female who developed autoimmune hepatitis a week after her first dose of the Pfizer COVID-19 vaccine. This led to a study being conducted in which the authors concluded there is a possibility that “spike-directed antibodies induced by vaccination may also trigger autoimmune conditions in predisposed individuals”.
The researchers Bril et al (2021) found that “severe cases of SARS-CoV-2 infection are characterised by an auto-inflammatory dysregulation that contributes to tissue damage,” which the virus’s spike protein appears to be responsible for. They also reported that histology revealed the presence of eosinophils, which are more commonly seen with drug or toxin-induced liver injury, although can also be found in cases of autoimmune hepatitis.
They argued that “It is also possible that we could be in the presence of a vaccine-related drug-induced liver injury with features of autoimmune hepatitis [….] symptoms developed 6 days after vaccination, which instinctively appears as a short period of time. However, latency periods after vaccination of just days have been observed in prior reports”.
We wonder if Chris Whitty will be able to sleep at night once the UKHSA proves the Covid-19 injection is to blame for this sudden increase in hepatitis among children? Afterall, not a single child would have been given the Covid-19 injection if it were not for the Chief Medical Officer for England overruling the Joint Committee on Vaccination and Immunisation which had previously concluded the benefits do not outweigh the risks.